Incannex Healthcare Files 8-K, Discloses Regulation FD Event
Ticker: IXHL · Form: 8-K · Filed: Mar 25, 2026 · CIK: 0001873875
| Field | Detail |
|---|---|
| Company | Incannex Healthcare Inc. (IXHL) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, press-release, corporate-disclosure
TL;DR
**Incannex just dropped an 8-K with a press release; check it for market-moving news!**
AI Summary
Incannex Healthcare Inc. filed an 8-K on March 25, 2026, to disclose a Regulation FD event, which typically means they've shared important non-public information. This filing includes a press release dated March 25, 2026, as Exhibit 99.1, which likely contains the specific details of this disclosure. Investors should pay close attention to the press release to understand the nature of this information, as it could significantly impact the company's future prospects and stock valuation.
Why It Matters
This filing signals that Incannex Healthcare has released material information that could affect its stock price, making it crucial for investors to review the accompanying press release immediately.
Risk Assessment
Risk Level: medium — The risk level is medium because the specific content of the Regulation FD disclosure is not detailed in the 8-K itself, requiring further investigation into the attached press release to assess its impact.
Analyst Insight
A smart investor would immediately locate and review the 'PRESS RELEASE DATED AS OF MARCH 25, 2026' (EX-99.1) to understand the specific details of the Regulation FD disclosure and assess its potential impact on Incannex Healthcare Inc.'s stock.
Key Numbers
- 2026-03-25 — Filing Date (The date the 8-K was filed and accepted by the SEC.)
- Item 7.01 — Regulation FD Disclosure (The specific item under which the material non-public information was disclosed.)
- Item 9.01 — Financial Statements and Exhibits (The item indicating the inclusion of exhibits, specifically the press release.)
- EX-99.1 — Press Release Exhibit (The exhibit number for the press release dated March 25, 2026, containing the core disclosure.)
Key Players & Entities
- Incannex Healthcare Inc. (company) — the filer of the 8-K
- 0001873875 (company) — CIK of Incannex Healthcare Inc.
- March 25, 2026 (date) — filing date and period of report
- 001-41106 (dollar_amount) — File No. for Incannex Healthcare Inc.
FAQ
What is the primary purpose of Incannex Healthcare Inc.'s 8-K filing on March 25, 2026?
The primary purpose of Incannex Healthcare Inc.'s 8-K filing on March 25, 2026, is to disclose a Regulation FD event under Item 7.01, indicating the release of material non-public information.
What specific exhibit is included in this 8-K filing that provides more details about the disclosure?
The 8-K filing includes a 'PRESS RELEASE DATED AS OF MARCH 25, 2026' as Exhibit 99.1, which is expected to provide the specific details of the Regulation FD disclosure.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 25, 2026, at 08:00:06.
What is Incannex Healthcare Inc.'s CIK number as stated in the filing?
Incannex Healthcare Inc.'s CIK number, as stated in the filing, is 0001873875.
Which SIC code is associated with Incannex Healthcare Inc. in this filing?
Incannex Healthcare Inc. is associated with SIC code 2834, which represents 'Pharmaceutical Preparations'.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2026-03-25 08:00:06
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq
Filing Documents
- ea028334201-8k_incannex.htm (8-K) — 25KB
- ea028334201ex99-1_incannex.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001213900-26-033842.txt ( ) — 214KB
- ixhl-20260325.xsd (EX-101.SCH) — 3KB
- ixhl-20260325_lab.xml (EX-101.LAB) — 33KB
- ixhl-20260325_pre.xml (EX-101.PRE) — 22KB
- ea028334201-8k_incannex_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated as of March 25, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Incannex Healthcare Inc. Date: March 25, 2026 /s/ Joel Latham Name: Joel Latham Title: Chief Executive Officer and President 2